MaxCyte beats Q3 EPS and revenue estimates, issues FY revenue guidance above consensus (MXCT:NASDAQ)
MaxCyte reported Q3 2026 GAAP EPS of -$0.05, beating estimates by $0.03. Revenue grew 49.3% year-over-year to $10.2M, exceeding expectations by $2.73M. The company issued FY revenue guidance above consensus. According to the company, total revenue included $8.2M from core operations and $2.0M from SPL Program-related activities.
How this was made
The 30-second read
Why it matters
The earnings beat on revenue may attract interest, but the negative EPS could keep the stock under pressure.
Market read
First-report earnings for a micro‑cap biotech; modest trading relevance.
What to watch
Potential pipeline milestones or upcoming contracts not disclosed in this release.
Background
MaxCyte released its Q3 2026 earnings, reporting a loss per share that beat estimates and a significant revenue increase.
Ticker impact
Q3 GAAP EPS of -$0.05 beats estimate and revenue of $10.2M (+49.3% YoY) beats estimate.
modest downside as market prices in the loss despite revenue beat
The company posted a small loss that beat expectations, but negative EPS often pressures the stock.
Market effects
Biotech/clinical services sector may see modest attention due to revenue growth.
Limited to US biotech investors.
Low global impact.
Counterpoint
Despite the loss, the strong revenue growth could support a short-term rally.
Key entities
- CompanyMaxCyte
Biotech firm providing cell engineering platforms.
